Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

John Klock

Emil D. Kakkis

Ultragenyx Pharmaceutical Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Jaya Biosciences is a privately held pre-clinical stage life sciences company developing therapies for genetically defined neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and frontotemporal dementia.

Jaya Biosciences

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.

Leading with purpose. Every day.“Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.”Emil D. Kakkis, M.D., Ph.D.Chief Executive Officer and PresidentWe have an inclusive culture of value and respect.Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community.  We put our people first, so they can take care of the rare disease community.We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment.If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team!Visit our community guidelines at: https://ultragenyx.co/community

Metric
Company Name	Ultragenyx Pharmaceutical Inc.	Ardelyx, Inc.	Jaya Biosciences	Rezolute, Inc.
Symbol	RARE	ARDX		RZLT
MSH ID	COM:ULTRAGENYX	COM:ARDELYX	COM:JAYABIO	COM:REZOLUTEBIO
Market	STOCKS	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage		Debt
Employee Count	1.28K	267		41
Website	ultragenyx.com	ardelyx.com	jayabio.com	rezolutebio.com
LinkedIn	ultragenyx-pharmaceutical-inc-
Founders

Metric
Market Cap	3.85B	1.30B	220.96M
Enterprise Value
Monthly Web Traffic	21.29K	33.50K
Web Traffic Growth	0.36	2.80
Valuation
Raised Capital	350M	20M

Metric
Revenue	434.25M	124.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	389.04M	106.66M
EBITDA	-516.85M	-55.35M
Operating Income	-569.21M	-63.28M
Net Income	-606.64M	-66.07M
EPS	-8.25	-0.30
Diluted EPS	-8.25	-0.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.90	0.86
Operating Profit Margin	-1.14	-0.28
EBITDA Margin	-1.19	-0.44
Net Profit Margin	-1.22	-0.31
Return on Equity	-2.66	-0.40
Return on Assets	-0.36	-0.19
Return on Capital Employed	-0.41	-0.21

COM:ULTRAGENYX

Ultragenyx Pharmaceutical Inc.

Last Close

46.02

22/11 21:00

Market Cap

3.85B

Beta: -

Volume Today

593.87K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.06	-74.58
P/B Ratio	101.28	10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.42	14.47
EV Multiple	-4.38	-20.25

Metric
Days Sales Outstanding	70.53	117.61
Days Payables Outstanding	316.43	185.33
Days Inventory Outstanding	274.25	264.91
Operating Cycle	335.94	329.52
Cash Conversion Cycle	51.68	100.07
Asset Turnover	0.34	0.61

Metric
Operating Cash Flow	-474.81M	-89.72M
Free Cash Flow	-521.57M	-90.06M
Cash Flow to Debt	-0.52	-0.77
Operating Cash Flow/Sales	-0.98	-0.41
Free Cash Flow Yield	-0.11	-0.03

Metric
Cash & Equivalents	213.58M	21.47M
Accounts Receivable	-22.78M	-14.30M
Inventory	33.97M	12.45M
Goodwill	44.41M
Debt to Capitalization	0.87	0.41
Debt to Assets	0.01	0.12
Current Ratio	2.06	5.54
Quick Ratio	3.39	4.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.32	0.09
R&D to Revenue	1.61	0.26
SG&A to Revenue		0.15